For the quarter ending 2026-03-31, EW made $1,648,600K in revenue. $380,700K in net income. Net profit margin of 23.09%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net sales | 1,648,600 | 1,569,600 | 1,553,100 | 1,532,200 |
| Cost of sales | 362,600 | 343,000 | 345,200 | 344,400 |
| Gross profit | 1,286,000 | 1,226,600 | 1,207,900 | 1,187,800 |
| Selling, general, and administrative expenses | 522,200 | 602,900 | 514,600 | 502,000 |
| Research and development expenses | 263,300 | 267,700 | 280,700 | 276,200 |
| Certain litigation expenses | 37,100 | 208,600 | 90,400 | 15,500 |
| Change in fair value of contingent consideration liabilities (note 13) | - | 25,000* | -12,500 | - |
| Restructuring charges and separation costs (note 3) | - | - | 100 | - |
| Restructuring charges, separation costs, and other (note 4) | - | 4,775* | - | - |
| Intangible assets impairment charges | - | -19,175* | 40,000 | - |
| Separation costs | 0 | - | - | 4,200 |
| Other operating income | 14,200 | 14,300 | 12,500 | 21,300 |
| Operating income, net | 477,600 | 151,100 | 307,100 | 411,200 |
| Interest expense | - | 5,100* | - | - |
| Interest income, net | 33,500 | 54,800* | 38,600 | 37,400 |
| Loss on impairment (note 6) | 123,600 | 113,600* | 0 | - |
| Loss on impairment | - | - | - | 47,100 |
| Other non-operating income, net (note7) | 71,500 | 3,200 | 2,700 | -1,300 |
| Income from continuing operations before provision for income taxes | 459,000 | 90,400 | 348,400 | 400,200 |
| Provision for income taxes | 78,300 | 26,200 | 56,100 | 64,300 |
| Net income from continuing operations | 380,700 | 64,200 | 292,300 | 335,900 |
| Net sales | - | - | 15,900 | - |
| Cost of sales | - | - | 9,200 | - |
| Gross profit | - | - | 6,700 | - |
| Selling, general, and administrative expenses | - | - | 5,900 | - |
| Research and development expenses | - | - | 1,400 | - |
| Separation costs | - | - | 1,900 | - |
| Operating loss, net | - | - | -2,500 | - |
| Other non-operating (income) expense, net | - | - | 0 | - |
| (loss) income from discontinued operations before provision for income taxes | - | - | -2,500 | - |
| (benefit) provision from income taxes from discontinued operations | - | - | -500 | - |
| Loss from discontinued operations, net of tax | 0 | 27,000 | -2,000 | -4,400 |
| Net income | 380,700 | 91,200 | 290,300 | 331,500 |
| Less net loss attributable to noncontrolling interest | 0 | 0 | -800 | -1,700 |
| Net income attributable to edwards lifesciences corporation | 380,700 | 91,200 | 291,100 | 333,200 |
| Basic EPS | 0.66 | 0.157 | 0.5 | 0.57 |
| Diluted EPS | 0.66 | 0.157 | 0.5 | 0.56 |
| Basic Average Shares | 579,200,000 | 580,600,000 | 584,700,000 | 587,000,000 |
| Diluted Average Shares | 580,700,000 | 581,800,000 | 585,700,000 | 587,900,000 |
Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (EW)